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The inhibition of DNA synthesis in chronic lymphocytic leukaemia cells
by chlorambucil in vitro
D.P. Bentley & J.A. Blackmore
Department ofHaematology, Llandough Hospital, Penarth, South Glamorgan CF6 IXX, UK
Summary The inhibition of 3H-thymidine incorporation into the DNA of mitogen-stimulated lymphocytes
from patients with chronic lymphocytic leukaemia by chlorambucil was measured in vitro and the results
related to clinical drug resistance. The assay proved to be both sensitive and specific showing a clear
separation of those patients with responsive disease from those with disease resistant to treatment. There was
evidence of primary drug resistance in untreated patients. In almost all patients who received treatment this
led to increasing resistance to chlorambucil in vitro. The assay is predictive of clinical responsiveness and
provides a potential means whereby new therapeutic agents and treatment modifiers may be investigated.
Chronic Lymphocytic Leukaemia (CLL) is an incurable
disease and although it is usually responsive to chemo-
therapy, treatment is reserved for symptomatic patients with
extensive lymphadenopathy, sweating or weight loss. In most
patients treatment with alkylating agents alone will produce
relief of symptoms accompanied by a reduction in lymph-
adenopathy and a fall in peripheral blood and bone marrow
lymphocyte infiltration (Gale & Foon, 1985). Although a
complete remission may be induced in a small proportion of
patients, it is probably not possible to eradicate the disease
even with intensive chemotherapy. In many patients increas-
ing resistance to chemotherapy leads ultimately to uncon-
trollable tumour cell proliferation and disease progression;
mortality, however, is often attributed to infection, the risk
of which may be increased by treatment.
The potential value of predictive drug sensitivity assays in
the selection of cytotoxic chemotherapy has been recognised
for many years (Weisenthal, 1981). This would be of partic-
ular benefit when the risks of therapy have to be carefully
weighed against the possible benefits. The value of several
different cytotoxicity assays has been investigated in patients
with lymphoproliferative disorders (Veerman & Pieters,
1990); low plating efficiency has limited the value of clono-
geneic assays in these disorders, while direct cytotoxicity
assay have produced some promising results (Weisenthal et
al., 1986; Twentyman et al., 1989; Bosanquet, 1991).
The purpose of the present study was to determine whether
the uptake of a DNA precursor (3H-thymidine) by CLL
lymphocytes was sensitive to the effects of chlorambucil in
vitro and whether such an approach could be used to predict
drug sensitivity in these patients.
Subjects and methods
Subjects
Twenty-four patients, 14 male and ten female, with CLL
were studied. Six of these had received previous treatment
and 18 remained untreated at the start of the study. Disease
stage was identified according to the classification of Binet et
al., (1981); 12 of the untreated patients were in stage A, four
in stage B and two in stage C. Lymphocytes were obtained
from 10 healthy normal volunteers for comparison.
Lymphocyte separation
Lymphocytes were separated from fresh venous blood
samples by differential sedimentation using a fully asceptic
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technique, which was maintained throughout. Ten ml of
heparinised blood were added to 14 ml of phosphate buffered
saline (PBS) pH 7.2 and 8.0 ml volumes of this dilution were
layered onto 3.0 ml of a solution of ficoll and sodium diatri-
zoate (Histopaque-1077, Sigma Chemical Co., Poole, Dorset,
UK) in conical centrifuge tubes and spun at 400g for 30 min.
The upper layers were aspirated to within 0.5 cm of the
opaque interface layers containing the lymphocytes and dis-
carded. The opaque interface layers were transferred into
clean conical centrifuge tubes and 10 ml PBS were added to
each and the whole contents mixed by inversion. The tubes
were then centrifuged at 250g for Omin and the super-
natants discarded. Erythrocyte contamination was removed
by lysis by the addition of 10 ml of 0.87% ammonium
chloride solution to the tubes which were left standing for
5 min at room temperature and then centrifuged at 250g for
10 min. The ammonium chloride solution was discarded and
the pellets washed with 10 ml PBS and again centrifuged at
250g for 10 min. All the lymphocytes separated from an
individual patient or normal subject were then pooled prior
to a final wash.
Lymphocyteproliferation
All cultures were undertaken using Eagle's Minimum Essen-
tial Medium (Gibco Ltd, Paisley, UK) supplemented with
0.22% sodium bicarbonate, 5% foetal calf serum, 10,000 iu
100ml-1 sodium benzyl penicillin and 5,000 ig lOOml-'
streptomycin. Culture solutions were sterilised by filtration
through 0.2 i membrane filters. The separated lymphocytes
were resuspended in this medium and the concentration
adjusted to 1 x 106 cellsml-'.
Cultures were performed in 2 ml microtubes (Sarstedt Ltd,
Leicester, UK). Preliminary studies had shown that the addi-
tion of 0.2 ml of autologous serum to 1.0 ml of lymphocyte
suspension produced optimal culture conditions. Fifty ;LI of a
solution of either 0.4pg ml-' pokeweed mitogen (PWM) in
PBS or 4 jigml-' phytohaemagglutinin (PHA) in PBS were
added to each tube depending on which mitogen had pre-
viously been shown, under identical culture conditions, to
produce the greater response in each individual patient.
Studies of normal lymphocytes were undertaken using solely
PWM.
Lymphocyte cultures were performed in triplicate except
those without inhibitors; these were performed in quintup-
licate. Fifty jl of chlorambucil solution diluted in PBS to
achieve final concentrations of between 0.5 and 20 igml-'
were added to each of up to eight triplicate cultures. Fifty gIl
PBS alone were added to the cultures without any inhibitor.
The chlorambucil solution was made up from pure powder
kindly supplied by Dr A.B.W. Nethersell, Wellcome Research
Laboratories, Beckenham, Kent, UK. Twenty-four mg were
dissolved in 1.0 ml ethyl alcohol and a stock solution was
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prepared by diluting this to 100 ml in PBS. The stock solu-
tion was kept frozen in aliquots at - 20°C, and although
there is no information available regarding the stability of
chlorambucil stored under these conditions (Bosanquet,
1985) solutions were never refrozen. One aliquot was thawed
on the day of use and diluted further in PBS to produce
concentrations of 0.5-10 tgml-' in the cultures. In some
instances additional stock solution was used to achieve a
higher final concentration.
All cultures were incubated at 37°C in 5% carbon dioxide
in humidified air for 66 h. Two fsCi (0.074 MBq) 3H-thymi-
dine (Amersham International Plc, Amersham, Bucks, UK)
in 0.1 ml PBS were then added and the cultures incubated for
a further 24 h.
Cell harvest
Lymphocytes were harvested by filtration through 2.5 cm
glass microfibre filter discs (Whatman Labsales Ltd, Maid-
stone, Kent, UK) using Whatman 3-piece filter funnel units
attached to a suction pump. The contents of each tube were
mixed and pipetted onto a filter disc; the tubes were washed
out three times with 2.0 ml cold PBS and the washings
filtered. The discs were finally washed through twice with
5.0 ml cold PBS.
Each disc was removed from its filter unit and left to dry
overnight at room temperature in a 20 ml scintillation vial
(Canberra Packard Ltd, Pangbourne, Berks, UK).
Scintillation counting
Five ml of scintillation fluid (Insta-Gel, Canberra Packard
Ltd, Pangbourne, Berks, UK) were added to each vial and
after capping and shaking all vials were chilled at 4°C for
45 min in the dark. Counting was performed in an Intertech-
nique SL 30 liquid scintillation spectrometer.
The mean of each triplicate set of readings was calculated
with the background counts subtracted. The percentage 3H-
uptake in each culture was calculated taking the uptake in
the control cultures without chlorambucil as 100%.
Results
A typical dose-response curve obtained using the lympho-
cytes from a normal subject is shown in Figure 1. The patient
data are shown in Tables I-III and Figure 2 shows the
Table I Mean 3H-thymidine incorporation (c.p.m.-background, in
lymphocytes cultured without chlorambucil), dose:response slope and
ID50 for normal subjects
3H-TdR ID50
Subject incorporation Slope tigmI-
A 86905 -0.216 1.3
B 87865 -0.088 3.0
C 83609 -0.191 1.5
D 122910 -0.244 1.3
E 47949 -0.109 2.1
F 106438 -0.114 2.6
G 59344 -0.117 2.3
H 125010 -0.209 0.9
I 100968 -0.169 1.6
J 118673 -0.205 1.6
K 111449 -0.190 1.2
L 180641 -0.209 1.3
Mean -0.172 1.7
SD ±0.051 ±0.6
dose-response curves obtained from one previously treated
and from one untreated patient.
There was a linear inverse relationship between the log
3H-thymidine uptake by the normal or the neoplastic
lymphocytes in culture and the chlorambucil concentration to
which they were exposed. The latter was examined over the
range 0.5-5pgml-1 for the normal lymphocytes, 0.5-7jig
ml-' for the untreated patients' lymphocytes and 0.5-25Ag
ml-' for the treated patients' cells in order to achieve a
thymidine uptake inhibition in excess of 70%. Data points
were fitted by least squares to a linear function of chlor-
ambucil concentration against log percentage lymphocyte 3H-
thymidine uptake. The slope ofeach curve and the chlorambu-
cil concentration required to achieve a 50% growth inhibition
(ID50) were calculated in each case. Comparisons of the
means for each group were made using the Mann-Whitney
non-parametric test and of repeat assays performed in the
same patient using the Wilcoxon Signed Rank Test.
The mean (± s.d.) ID50 for normal lymphocytes was
1.7 ± 0.5 (range 0.9-2.5)fig chlorambucil ml-' and the mean
(± s.d.) slope of the dose-response curves was -0.180 +
0.048 (range -0.1 17 to -0.244).
For the lymphocytes from the untreated patients the mean
(± s.d.) ID50 was 3.1 ± 1.3 (range 1.1-6.5)fig mlh'. This is
significantly higher than that for the normal lymphocytes
(U = 18.5, P= 0.0007). The mean (± s.d.) slope of the dose:
response curves in these patients was - 0.095 ± 0.028 (range
Table II Clinical stage, absolute lymphocyte count, mean 3H-thymidine incorporation
(c.p.m.-background, in control cultureswithout chlorambucil), dose:response slopeandID50
for 18 untreated CLL patients
Absolute lymphocyte
count x 109-''
95.6
14.6
17.4
19.7
13.7
55.6
21.3
105.8
51.2
136.0
33.6
67.4
34.3
449.0
218.4
44.3
110.1
49.9
3H-TdR
incorporation
7413
17433
10675
17317
10735
15252
14505
5640
13392
11706
30601
9430
17926
3718
11356
19094
5822
8614
Mean
SD
Slope
-0.138
-0.098
-0.094
-0.107
-0.077
-0.069
-0.108
-0.101
-0.119
-0.060
-0.079
-0.122
-0.062
-0.123
-0.146
-0.049
-0.096
-0.074
-0.095
± 0.028
ID
tigm&1-
1.8
3.3
1.1
2.9
3.7
3.2
2.5
3.2
3.4
6.5
1.7
2.5
3.0
2.4
2.2
5.5
3.5
2.7
3.1
±1.3
Patient
no.
001
002
003
004
005
006
007
008
009
010
011
012
013
014
015
016
017
018
Stage
A
A
A
A
A
A
A
A
A
A
A
A
B
B
B
B
C
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Table III 3H-thymidine incorporation (c.p.m.-background, in control cultures without chloram-
bucil), dose:response slope and ID50 and pre-treatment and post-treatment absolute lymphocyte
counts in CLL patients
Absolute lymphocyte count
3H-TdR ID50 Pre-treatment Post-treatment
Patient no. incorporation Slope figmlt' x 109 1 ' x 109 1-'
Responsive patients
011 10790 -0.079 1.7 34 9
011 21441 -0.115 1.5 59 18
011 23112 -0.090 2.9 66 30
012 9430 -0.122 2.5 175 66
013 17926 -0.094 1.9 56 23
013 8582 -0.062 3.0 53 14
014 3817 -0.123 2.4 729 152
015 17433 -0.146 2.2 218 64
017 5822 -0.096 3.5 110 5
018 8614 -0.074 2.7 50 5
Mean -0.100 2.4
SD ±0.026 ±0.6
Non-responsive patients
012 17584 -0.064 4.6 159 160
015 34603 -0.050 4.1 65 50
019 15067 -0.130 4.8 278 473
020 5226 - 0.036 8.7 78 98
020 4719 -0.023 13.8 193 139
021 3017 -0.036 7.0 52 48
021 12543 -0.055 4.1 28 27
021 11278 -0.023 15.7 105 144
Mean -0.052 7.8
SD ±0.039 4.6
Refractory patients
019 11685 -0.066 4.6 121 -
020 9331 -0.017 21.6 139 -
022a 5683 - 0.034 9.3 132 -
023a 6596 -0.017 14.1 690 -
024 14084 -0.078 6.0 123 -
Mean -0.042 11.1
SD ± 0.028 ± 6.9
aIndicates those patients in whom lymphocytes were stimulated with PHA. All others were
stimulated with PWM.
100
80
60
c
0
0._
o
0
EC
~0
Q
I
40
20
10l
inn-
-0
0 0.
4
0
C)
L-
o C.)
cr:
ID
lvv-
80
60
40
20
1u
0 1.0 2.0 3.0 4.0 5.0
Chlorambucil concentration jig ml
III~~ ... .I I.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 1718
Chlorambucil concentration ,ug ml-1
Figure 2 The effect of chlorambucil on 3H-thymidine uptake by
mitogen-stimulated CLL lymphocytes; 0, untreated patient,
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Figure 1 The effect of chlorambucil on 3H-thymidine uptake by
normal mitogen-stimulated lymphocytes.
-0.049 to -0.146) and this is significantly lower than that
for the normal cells (U = 13.5, P = 0.0003). In these patients
the slope of the dose:response curve and the ID50 were
unrelated to the disease stage or peripheral blood lymphocyte
count. Regression of the dose-response curve for normal
lymphocytes to zero growth inhibition produced a mean IDo
of -0.14ggml' (range -0.55 to 0.0 Lgml'). In the un-
treated patients negative values for IDo in the range -2.0 to
-0.58 ig ml-' were found in eight patients and positive
values between 0.014 and 0.80jg ml' in the remaining ten;
the mean value was -0.44fig ml-'. Thus there was no clear
evidence of a threshold concentration to be exceeded before
there was any detectable effect from the presence of chloram-
bucil.
The linearity of the dose-response curve was tested by
examination of the deviation of the observed values and the
mid-point of the line constructed between the first and last174 D.P. BENTLEY & J.A. BLACKMORE
data points in each case. In all but one of the untreated
patients this gave a negative value (range -0.002 to -0.28)
indicating that the dose-response curves were concave up-
wards and the median deviation for the group was -0.066;
this was significantly different from that found for the nor-
mal subjects (median deviation 0.008, U = 26.0, P = 0.007) in
whom there was no evidence of deviation from linearity.
In 18 instances (11 patients) treatment with chlorambucil
was administered after the patient's lymphocyte sensitivity
had been measured and the data are shown in Table III. In
ten instances the peripheral blood lymphocyte count fell to
less than 50% (range 4-42%) of the pre-treatment level,
indicative of a satisfactory response to treatment. In six
instances there was a failure of response when the lympho-
cyte count was unchanged or increased following treatment
and in the remaining two the post-treatment lymphocyte
counts were 72% and 76% of the pretreatment values, these
latter patients being collectively regarded as being clinically
non-responsive to treatment. The responsive patients had a
significantly higher dose:response curve slope (mean + s.d.,
0.100 ± 0.026, U = 10.0, P=0.009) and lower ID5o(mean ± s.d.
2.42 ± 0.62 fig ml-', U = 0, P = 0.0005) than the non-respon-
sive patients (mean ± s.d. slope was 0.052 ± 0.039, mean +
s.d. ID50 was 7.83 ± 4.58 jIg ml-'). The IDso values for the
non-responsive patients were in every case greater than
4.1 jig ml-' whereas for the responsive patients these were all
less than 3.5 fig ml-' (Figure 3). In two untreated patients,
who have still not required any treatment, the ID50 was
greater than 4 jig ml-'.
Five patients (all stage C) previously found to be refrac-
tory to treatment including alkylating agents, anthracyclines
and cortico-steroids were investigated. Their mean (± s.d.)
ID50 was 1.1 (± 6.9) fig ml- and this was significantly
higher than that of the untreated patients (U = 3.0, P=0.002),
and that of the responsive patients (Figure 3, U = 0,
P = 0.003). Similarly the slope of the dose:response curves
(mean + s.d., 0.042 ± 0.028) for these patients was signifi-
cantly lower (U = 9.0, P = 0.008) than that of the untreated
patients. Each of these patients initially received treatment
with chlorambucil and all have subsequently died after an
interval of between 4 and 10 months after their lymphocytes
were studied.
In ten instances (six patients) lymphocyte sensitivity was
studied before and after the patient had received treatment
with chlorambucil. On six of these occasions treatment was
given for the first time, but in the remainder the patients had
received treatment on at least one previous occasion. In all
instances, apart from in one patient with continously respon-
sive disease, the post-treatment ID50 was greater than the
pretreatment level (Table IV, Figure 4), although in one
instance this was by only 2.4%. This increase was highly
significant (W = - 51.0, P = 0.006). In several patients serial
studies were undertaken and an increasing ID50 was
associated with increasing clinical resistance to therapy. A
typical example is shown in Figure 5.
Discussion
Chlorambucil is a bifunctional alkylating agent with cyto-
toxic activity dependent on the formation of cross links
between complementary strands of DNA (Silber et al., 1989).
It has been used extensively in the treatment of CLL to
induce gradual cytoreduction and thereby reduce tissue infil-
tration. Treatment with an alkylating agent alone remains the
standard therapy for CLL and although the use of more
intensive combination chemotherapy has been more effective
in some patients this latter approach has still failed to induce
remissions in a substantial proportion of CLL patients
(French Cooperative Group on Chronic Lymphocytic Leu-
kaemia, 1986; Monserrat et al., 1985). Furthermore most
CLL patients will ultimately become resistant to the effect of
treatment and the management of resistant disease has prov-
ed to be difficult and hazardous; many patients will succumb
to intercurrent infection, the risk of which may be enhanced
Table IV Effect oftreatment on the dose-response curve examined in
six patients in ten instances
Pre-treatment Post-treatment
Patient no. ID50 ID50
Slope jigmlt Slope jigml'
011 -0.079 1.7 -0.115 1.5
011 -0.090 2.9 -0.0.98 3.0
012 -0.122 2.5 -0.0.64 4.6
012 -0.064 4.6 -0.060 5.5
013 -0.094 1.9 -0.094 4.2
013 -0.094 4.2 -0.038 8.1
014 -0.123 2.4 -0.050 5.8
015 -0.146 2.2 -0.050 4.1
015 -0.050 4.1 -0.044 7.6
017 -0.096 3.5 -0.060 5.1
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Figure 3 Chlorambucil ID50 for CLL lymphocytes in vitro in ten
instances when there was a satisfactory response to treatment,
eight when the disease was non-responsive to treatment (arrows
indicate those patients showing a partial response) and in five
patients known to be refractory to treatment. * indicates those
patients whose lymphocytes were stimulated with PHA.
by treatment. The value of predictive chemotherapy sensi-
tivity assays in this situation is clear, particularly when the
therapeutic margins of safety are narrowed by prior treat-
ment-induced myelosuppression.
Direct in vitro cytotoxicity assays have previously been
applied in leukaemias (Weisenthal et al., 1986; Twentyman et
al., 1989) and have been shown to be of predictive value in
the management of these disorders (Bosanquet, 1991; Hansen
et al., 1991). The MTT assay, which depends on the ability of
viable cells to reduce a tetrazolium salt, and dye exclusion
assays are the most widely studied of these. These assays
undoubtedly have the advantage of simplicity, speed, lack of
dependence on cell division and application to a wide variety
of tumours and drugs.
The present study, however, examines sensitivity by the
effect of the drug on precursor incorporation into the DNA
ofmitogen-stimulated CLL lymphocytes. Robert et al. (1978)
and Isakovic and Lenert (1987) have demonstrated that CLL
cells are responsive to PHA and to PWM. In the present
study stimulation of DNA synthesis by PWM produced suffi-
cient 3H-thymidine uptake to produce satisfactory dose:res-
ponse curves except in two subjects in whom it was necessary
to use PHA as the mitogen. Both of these patients were
included with those patients previously found to be refrac-
tory to treatment and their data not used in the predictive
part of the study. In general, however, there was a much
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Figure 4 Chlorambucil IDofor CLL lymphocytes in ten instan-
ces in six patients in whom sensitivity was tested before and after
treatment.
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Figure 5 Chlorambucil ID50 and peripheral blood lymphocyte
counts in a patient treated with chlorambucil (10-20 mg daily for
2-3 days intermittently) over 38 months.
lower rate of thymidine incorporation in the patients' cells
than into stimulated normal lymphocytes; it will require
parallel studies to determine whether the choice of mitogen
used influences the results of the assay. Johnstone et al.
(1982) suggested that PHA responsiveness in the lymphocytes
from CLL patients was primarily due to residual normal
cells. In the present study no attempt was made to remove
the normal lymphocytes but the data, however, demonstrate
a qualitative and a quantitative difference in chlorambucil-
induced suppression of DNA synthesis in the patients' lymphocytes compared to that in the normal subjects' lymphocytes. In the untreated patients there was a abnormal
loss of linearity in the dose:response curves which indicated
that a proportion of the cells had a greater resistance to the
effects of chlorambucil than did the majority oflymphocytes in the population under study. This is a feature ofmalignant cells and has been demonstrated in other cell lines (Bech-
Hansen et al., 1977). Siena et al. (1989) have demonstrated
inhibition of DNA synthesis in stimulated CLL cells by an
immunotoxin in vitro and Kernand Weisenthal (1990) have
shown that highly predictive data can be obtained by
measurement of the inhibition of DNA synthesis in solid
tumour tissue by the action of cytotoxic drugs in vitro.
The current assay has demonstrated the characteristics of
chlorambucil cytotoxicity in a highly quantifiable manner. It
is possible to describe the dose-response curve by a single
exponential function and the mean (± s.d.) correlation coeffi-
cient (r) was -0.971 (± 0.032). The values of the ID50 and
slope of the curve were readily calculated in every case once
the appropriate range of chlorambucil concentrations for an
individual subject's lymphocytes had been established.
The untreated patients showed a sensitivity to a concentra-
tion of chlorambucil of the same order of that achievable in
vivo and similar to those used in direct cytotoxicity assays
(Bosanquet et al., 1983; Bosanquet, 1991). Exposure of the
cells to chlorambucil was, however, continuous over a period
of 4 days in the current assay. There is evidence (Kern &
Weisenthal, 1990) that prolonged exposures to the cytotoxic
agent at high concentrations are necessary in order to pro-
duce valid results in this type of assay.
The results of this small pilot study provide evidence of
primary drug resistance in untreated patients; moreover the
ID50 values found in those patients in whom there was
clinical evidence of chlorambucil resistance were higher than
those of patients found to be sensitive to treatment without
any overlap between the two groups. Furthermore the evolu-
tion of clinical resistance could be identified; in all but one
instance the ID50 increased with treatment and this was
related to a fall in the slope of the dose:response curve.
Increasing drug resistance is likely to result from selective
elimination of the more sensitive tumour cells although the
effect of conditioning of surviving individual cells by expo-
sure to the drug cannot be excluded. In the present study in
vitro chlorambucil resistance appeared to be irreversible
although sufficiently long-term studies required to confirm
this have not yet been undertaken. The refractory patients
showed an increase in cellular resistance to chlorambucil
which appears to be maintained in vivo for many months
after withdrawal of treatment and into the terminal phase of
the disease.
The present data do not provide any indication of the
mechanism of drug resistance in these patients. Increased
activity of a membrane efflux pump mechanism has been
identified in some patients with leukaemia (Kuwazuru et al.,
1990), but this is not thought to be relevant in chlorambucil
resistance. Bank et al. (1989) have shown an equally rapid
cytoplasmic uptake of chlorambucil in chemotherapy-resis-
tant and chemotherapy-sensitive CLL cells. Drug neutralisa-
tion by increased intracellular glutathione (GSH) levels
(Suzukake et al., 1983) has been suggested Silber et al.
(1989) found no difference in the GSH content of CLL
lymphocytes compared to that of normal lymphocytes,
although they did find intracellular GSH levels unstable in
CLL cells in the presence of chlorambucil. In contrast to the
present finding, these workers found normal lymphocyte
viability less sensitive to the effects ofchlorambucil than were
CLL lymphocytes. Johnston et al. (1990) demonstrated a
correlation between DNA cross link formation by chloram-
bucil in CLL cells and the product of the intracellular GSH
level and glutathione S-transferase activity, but the number
of cross links formed was not related to clinical drug sen-
sitivity in their patients. The importance ofintracellular GSH
in modulating chlorambucil sensitivity merits further investi-
gation.
The current assay has demonstrated a means by which
chlorambucil sensitivity in CLL may be predicted and may
provide a useful tool for the investigation of resistance
mechanisms, the efficacy of new therapeutic agents or the
effect of response modifiers. It has demonstrated that there is
primary chlorambucil resistance established in some of the
leukaemic cells prior to drug exposure. Therefore condition-
ing mechanisms may not be important and treatment strate-
gies should be directed to the elimination of these resistant
subclones at the timeof first therapeutic intervention; current
suppressive treatment serves inevitably to generate more
resistant disease probably by selection of cells with a greater
capacity to resist the effects of chlorambucil.
We are grateful to Mrs M. Watkins for providing the secretarial
support.
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